Context Therapeutics (FRA:6K9) Net Issuance of Preferred Stock : €0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Context Therapeutics Net Issuance of Preferred Stock?

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares.

Context Therapeutics's net issuance of preferred for the three months ended in Mar. 2024 was €0.00 Mil. The number is 0, which means that Context Therapeutics has paid equal amouunt of cash to buy back preferred shares to the amount it received for issuing preferred shares quarterly.

Context Therapeutics's net issuance of preferred for the trailing twelve months (TTM) ended in Mar. 2024 was €0.00 Mil.

Context Therapeutics Net Issuance of Preferred Stock Historical Data

The historical data trend for Context Therapeutics's Net Issuance of Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Context Therapeutics Net Issuance of Preferred Stock Chart

Context Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Net Issuance of Preferred Stock

0.82

4.41

Context Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Issuance of Preferred Stock	Get a 7-Day Free Trial													-	-	-	-	-

Context Therapeutics Net Issuance of Preferred Stock Calculation

A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Net Issuance of Preferred Stock for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Context Therapeutics Net Issuance of Preferred Stock Related Terms

Thank you for viewing the detailed overview of Context Therapeutics's Net Issuance of Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.

Context Therapeutics (FRA:6K9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Context Therapeutics Inc (FRA:6K9) » Definitions » Net Issuance of Preferred Stock

Comparable Companies

Traded in Other Exchanges

CNTX:USA 6K9:Germany

Address

2001 Market Street, Suite 3915, Unit No. 15, Philadelphia, PA, USA, 19103

Website

https://www.contexttherapeutics.com

Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer.

Context Therapeutics (FRA:6K9) Headlines

No Headlines